Protalix BioTherapeutics enters $20M at-the-market equity offering with H.C. Wainwright

Protalix BioTherapeutics, Inc.

ATM offering of up to $20M of common stock via H.C. Wainwright & Co. as sales agent.
Proceeds for general corporate purposes, including working capital and clinical trials.
Shares sold on NYSE American at prevailing market prices in 'at the market' transactions.
Agreement supplements existing July 2021 ATM facility (amended May 2022).
Offered under existing shelf registration statement (Form S-3, No. 333-264394).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Protalix BioTherapeutics, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at shares of common stock with aggregate offering price of up to $20,000,000 (effective 2023-02-27).

Action: entry
Agreement: atm program
Counterparty: H.C. Wainwright & Co., LLC
Value: shares of common stock with aggregate offering price of up to $20,000,000
Effective: 2023-02-27

Exact text from the filing

On February 27, 2023, Protalix BioTherapeutics, Inc., a Delaware corporation (the "Company") entered into an At The Market Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC, as the Company’s sales agent (the "Agent").

View on SEC.gov

622 material agreements filed in the last 30 days. Browse all material agreements →

Protalix BioTherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-002104

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.